Related Experiment Video
Updated: Sep 16, 2025
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
Published on: April 13, 2015
Deep learning-based quantification of tumor-infiltrating lymphocytes as a prognostic indicator in nasopharyngeal
1NHC Key Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, China; Jiangxi Medical College, Nanchang University, Nanchang, China; JXHC Key Laboratory of Tumour Metastasis, Jiangxi Cancer Hospital, Nanchang, China; JXHC Key Laboratory of Tumor Microenvironment and Immunoregulation, Jiangxi Cancer Hospital, Nanchang, China.
Background:
Nasopharyngeal carcinoma (NPC) features a tumor-immune microenvironment rich in tumor-infiltrating lymphocytes (TILs), important for prognosis but labor-intensive to quantify. This study evaluates a deep learning model to quantify TILs (TILDL) in hematoxylin and eosin (H&E)-stained whole-slide images (WSIs) of NPC and explores the association of TILDL percentage with patient outcomes and response to immune checkpoint blockade (ICB).
Methods:
We retrospectively analyzed 435 nonmetastatic NPC patients from two centers, divided into a training cohort (n = 220) and a validation cohort (n = 215). An additional cohort of de novo metastatic NPC patients receiving ICB therapy (n = 63) was included. The deep learning model calculated TILDL percentages from H&E-stained WSIs. Correlations between TILDL percentages and immunohistochemistry (IHC)-derived TIL densities were assessed. Survival analyses evaluated their prognostic significance.
Results:
TILDL percentages showed strong correlations with IHC-derived TIL densities (CD3+ T cells R = 0.46, CD8+ T cells R = 0.33, CD20+ B cells R = 0.57; all P < 0.001). Higher TILDL percentages (median ≥45.7%) were associated with better 5-year disease-free survival (DFS) and overall survival (OS) in both training (DFS: 80.6% versus 62.5%, P = 0.016; OS: 84.4% versus 71.8%, P = 0.025) and validation cohorts (DFS: 87.3% versus 74.3%, P = 0.016; OS: 93.7% versus 82.6%, P = 0.010). In the ICB-treated metastatic cohort, higher TILDL percentages predicted better 3-year progression-free survival (PFS: 40.5% versus 25.0%, P = 0.022). Multivariate analyses confirmed TILDL percentage as an independent prognostic factor in both settings.
Conclusions:
The TILDL percentage derived from H&E-stained WSIs effectively stratifies risk in nonmetastatic NPC and may serve as a biomarker in metastatic NPC treated with ICB, aiding in patient selection for individualized treatment.
